TARRYTOWN, N.Y., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive three-year (156-week) data for EYLEA HD ® (aflibercept) Injection 8 mg from ...

At three years of EYLEA HD treatment, the vast majority of patients maintained visual and anatomic improvements while achieving extended dosing regimens, including those of just twice a year: 77%, 58% ...

88% of EYLEA HD patients had a last assigned dosing interval of ≥12 weeks at week 156, while sustaining visual and anatomic improvements achieved in the first 96 weeks, in this extension study of the ...

Results add to growing body of evidence showing ability of EYLEA HD to extend dosing intervals, including previously presented data in diabetic macular edema following three years of EYLEA HD ...

In PULSAR, EYLEA HD patients were initially randomized at baseline to either 3- or 4-month dosing intervals (after three initial monthly doses). If pre-specified criteria were met, dosing intervals ...

In PHOTON, EYLEA HD patients were initially randomized at baseline to either 12- or 16-week dosing intervals (after three initial monthly doses). If pre-specified criteria were met, dosing intervals ...